Hypochondroplasia

Hypochondroplasia is a genetic skeletal dysplasia characterized by short stature with disproportionately short limbs, particularly affecting the proximal segments (rhizomelia). It is one of the most common forms of short-limbed dwarfism and is clinically milder than the related condition achondroplasia. Hypochondroplasia is caused by mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, with the most common mutation being Asn540Lys, found in approximately 50-70% of clinically diagnosed cases. The condition primarily affects the skeletal system, leading to short stature that typically becomes apparent in early to mid-childhood, with adult height usually ranging from approximately 120 to 150 cm. Key clinical features include short limbs relative to the trunk, mild to moderate short stature, broad and short hands and feet, lumbar lordosis (increased inward curvature of the lower back), limited elbow extension, and a relatively large head (macrocephaly). Unlike achondroplasia, the facial features in hypochondroplasia are usually normal or only mildly affected, and the characteristic facial features of achondroplasia (frontal bossing, midface hypoplasia) are generally absent or subtle. Some individuals may develop spinal stenosis (narrowing of the spinal canal) in adulthood, which can cause neurological symptoms such as leg pain, numbness, or weakness. Mild intellectual disability or learning difficulties have been reported in a subset of patients, though most individuals have normal intelligence. There is currently no cure for hypochondroplasia. Management is primarily supportive and symptomatic, focusing on monitoring growth, orthopedic complications, and spinal stenosis. Growth hormone therapy has been used in some cases with variable results in improving final adult height. Surgical interventions such as limb lengthening procedures may be considered in some patients. Spinal decompression surgery may be necessary for individuals who develop symptomatic spinal stenosis. Regular follow-up with a multidisciplinary team including geneticists, orthopedic specialists, and neurologists is recommended. Vosoritide, a C-type natriuretic peptide analog approved for achondroplasia, is being investigated for potential use in hypochondroplasia but is not yet an established treatment for this condition.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Hypochondroplasia